Hypercholesterolemia Drugs Market : Key Players, Growth, Analysis 2018 to 2024

Hypercholesterolemia Drugs Market report provides the latest market data along with industry future trends, which keeps tracking of users driving revenue growth rate of Hypercholesterolemia Drugs Market by drug class (statins and non-statins), type of disease (FH and non-FH), mechanism of action (bile acid sequestrants, HMG-coa reductase inhibitors, fibric acid derivatives, nicotinic acid and others) market status and outlook of global and major regions, from manufacturers, and end industries. As this report is expected to help key players among the Hypercholesterolemia Drugs Market it includes the five years Industry analysis and the 6 years annual forecast from 2018 to 2024. Some of the prominent participants in the Global Hypercholesterolemia Drugs Market are Aegerion Pharmaceuticals, Amgen Inc., AbbVie Inc., Eli Lilly, Merck &Co.Inc., Pfizer Inc., Sanofi S.A., Teva Pharmaceuticals, Cipla Limited and Novartis. According to report the global hypercholesterolemia drugs market is projected to grow at a CAGR of 4.7% over the forecast period of 2018-2024.

The presence of high level of cholesterol in the blood is known as Hypercholesterolemia or High cholesterol. Fatty deposits in the walls of the coronary arteries is formed due excess cholesterol present in the blood. As the cholesterol accumulates, it causes atherosclerotic plaques to form, which narrows and hardens the artery walls and reduces the supply of blood to the heart. This increases the risk of angina and heart attack. High-density lipoprotein (HDL) cholesterol, Low-density lipoprotein (LDL) cholesterol, Very low-density lipoprotein (VLDL) cholesterol are the types of Human blood cholesterol.

Growing Responsiveness to Heart Diseases Associated with Aging Population is the Key Factor Driving the Growth of the Market

Additionally, availability of funding and activities to promote health awareness programs by healthcare centers, rise in incidence of cardiovascular diseases and increasing awareness among people for reducing the harmful cholesterol levels to control heart diseases such factors are likely to boost the growth in this market. Statins is expected to be largest segment among the drug class in 2016. Statins helps to reduce blood cholesterol levels, bring down the danger of chest pain, heart attack, and stroke caused by a blocked blood vessel.

North America to Witness the Highest Growth during the Forecast Period

Among the geographies, North America is expected to be largest market for hypercholesterolemia drugs due to increasing incidences of heart diseases and related disorders in the region. While, Asia-Pacific is expected to grow fast during the forecast period, owing to the presence of a large pool of patient and growing government initiatives in countries like China and India is likely to augment the growth in this region.

Segment Covered in this Research Report

The report on global hypercholesterolemia drugs market covers segments such as, drug class, type of disease and mechanism of action. On the basis of drug class the global hypercholesterolemia drugs market is categorized into statins and non-statins. On the basis of type of disease the global hypercholesterolemia drugs market is categorized into FH and non-FH. On the basis of mechanism of action the global hypercholesterolemia drugs market is categorized into bile acid sequestrants, HMG-coa reductase inhibitors, fibric acid derivatives, nicotinic acid and others.

Major Key Players Mentioned in this Research Report

The report provides profiles of the companies in the global hypercholesterolemia drugs market such as, Aegerion Pharmaceuticals, Amgen Inc., AbbVie Inc., Eli Lilly, Merck &Co.Inc., Pfizer Inc., Sanofi S.A., Teva Pharmaceuticals, Cipla Limited and Novartis.

Report Highlights:

The report provides deep insights on demand forecasts, market trends and micro and macro indicators. In addition, this report provides insights on the factors that are driving and restraining the global hypercholesterolemia drugs market. Moreover, IGR-Growth Matrix analysis given in the report brings an insight on the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter’s five forces analysis and DRO analysis of hypercholesterolemia drugs market. Moreover, the study highlights current market trends and provides forecast from 2018-2024. We also have highlighted future trends in the hypercholesterolemia drugs market that will impact the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight on the market share of the leading players. This report will help manufacturers, suppliers and distributors of the hypercholesterolemia drugs market to understand the present and future trends in this market and formulate their strategies accordingly.

Table of Contents:-

1. Preface

1.1. Report Description

1.2. Research Methods

1.3. Research Approaches

2. Executive Summary

3. Global Hypercholesterolemia Drugs Market Overview

3.1. Introduction

3.2. Market Dynamics

3.2.1. Drivers

3.2.2. Restraints

3.2.3. Opportunities

3.3. Porter’s Five Forces Analysis

3.4. IGR-Growth Matrix Analysis

3.5. Competitive Landscape in the Global Hypercholesterolemia Drugs Market

4. Global Hypercholesterolemia Drugs Market by Drug Class

4.1. Statins

4.2. Non-Statins

5. Global Hypercholesterolemia Drugs Market by Type of Disease

5.1. FH

5.2. Non-FH

6. Global Hypercholesterolemia Drugs Market by Mechanism of Action

6.1. Bile Acid Sequestrants

6.2. HMG-Coa Reductase Inhibitors

6.3. Fibric Acid Derivatives

6.4. Nicotinic Acid

6.5. Others

7. Global Hypercholesterolemia Drugs Market by Region 2018-2024

7.1. North America

7.1.1. North America Hypercholesterolemia Drugs Market by Drug Class

7.1.2. North America Hypercholesterolemia Drugs Market by Type of Disease

7.1.3. North America Hypercholesterolemia Drugs Market by Mechanism of Action

7.1.4. North America Hypercholesterolemia Drugs Market by Country

7.2. Europe

7.2.1. Europe Hypercholesterolemia Drugs Market by Drug Class

7.2.2. Europe Hypercholesterolemia Drugs Market by Type of Disease

7.2.3. Europe Hypercholesterolemia Drugs Market by Mechanism of Action

7.2.4. Europe Hypercholesterolemia Drugs Market by Country

7.3. Asia-Pacific

7.3.1. Asia-Pacific Hypercholesterolemia Drugs Market by Drug Class

7.3.2. Asia-Pacific Hypercholesterolemia Drugs Market by Type of Disease

7.3.3. Asia-Pacific Hypercholesterolemia Drugs Market by Mechanism of Action

7.3.4. Asia-Pacific Hypercholesterolemia Drugs Market by Country

7.4. RoW

7.4.1. RoW Hypercholesterolemia Drugs Market by Drug Class

7.4.2. RoW Hypercholesterolemia Drugs Market by Type of Disease

7.4.3. RoW Hypercholesterolemia Drugs Market by Mechanism of Action

7.4.4. RoW Hypercholesterolemia Drugs Market by Sub-region

8. Company Covered

8.1. Aegerion Pharmaceuticals

8.2. Amgen Inc.

8.3. Abbvie Inc.

8.4. Eli Lilly

8.5. Merck & Co.inc.

8.6. Pfizer Inc.

8.7. Sanofi S.a.

8.8. Teva Pharmaceuticals

8.9. Cipla Limited

8.10.Novartis

Browse Detailed TOC, Description and Companies Mentioned in Report @ https://www.infiniumglobalresearch.com/healthcare_medical_devices/global_hypercholesterolemia_drugs_market



Reset Password